What an experience! Osgoode’s team is back from their weekend of competition at the Harold G. Fox Intellectual Property Moot, and boy did we get a ‘bargain’! (more…)
Month: February 2014
in Feature Post, IP Reform, Patent Practice, Patentability, Patents, Pharmaceutical Drugs0by Editor
1101
China’s Bitter Medicine for Gilead: SIPO Cancels Viread Patent
Last August, China’s State Intellectual Property Office (SIPO) invalidated the core patent for Gilead Sciences‘ flagship drug Viread (as was reported by IPR Daily and a number of other news sources). This…
The Safety of Nova Scotia's New Cyber-Safety Act
A Nova Scotia court has issued the first order under the new Cyber-safety Act. Some critics have claimed the Act as being overly broad and unfair, while the government has defended…
“World War Pink”: Victoria’s Secret and Thomas Pink Square Off in Dispute Over “Pink” Brands
The global branding dispute between Thomas Pink and Victoria’s Secret opened up a front in Canada last month. In the decision, Justice Hughes of the Federal Court found that Victoria’s…
Reality Check: Federal Court Rejects Bridgestone’s Hypothetical Channels of Trade Argument in Confusion Analysis
The Federal Court recently dismissed an appeal from the Trade-marks Opposition Board regarding confusion between trade-marks for Bridgestone’s motor tires and Campagnolo’s specialty bike accessories. What made this case especially…
Talking “Open Innovation” in Plant Genetic Resources for Food and Agriculture
The contemporary global order for the promotion of innovation exaggerates the role of intellectual property (IP) as a closed proprietary model of knowledge production and protection. Partly as a boomerang…